Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT00429793Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2007
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temsirolimus in ovarian epithelial cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by National Cancer Institute. Primary endpoints: 6 Month Progression-free Survival, Objective Tumor Response up to 5 years and 1 more. Started Feb 2007; status: completed.
02
Drugs
temsirolimus
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00429793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00429793.